Terapia com células CAR-T no lúpus eritematoso sistêmico refratário: uma revisão integrativa
Article Sidebar
Main Article Content
Abstract
Introdução: A terapia com células CAR-T tem emergido como uma abordagem inovadora no tratamento de doenças autoimunes, assim como o lúpus eritematoso sistêmico (LES), especialmente em casos refratários às terapias convencionais. Objetivo: Avaliar o potencial terapêutico das células CAR-T no manejo do LES. Métodos: Realizou-se uma revisão integrativa da literatura nas bases PubMed e Embase, incluindo estudos clínicos publicados entre 2010 e fevereiro de 2026. A seleção dos artigos foi conduzida por meio da análise de títulos, resumos e textos completos, conforme critérios de elegibilidade previamente definidos. Resultados: Foram identificados 41 estudos, dos quais 4 atenderam aos critérios de inclusão. Os estudos, publicados entre 2023 e 2025, apresentaram amostras reduzidas e predominância de séries de casos. Observou-se redução da atividade da doença, remissão clínica e diminuição da dependência de imunossupressores, com perfil de segurança considerado aceitável. Conclusão: A terapia com células CAR-T demonstra potencial terapêutico relevante no LES refratário, embora as evidências ainda sejam limitadas. Estudos com maior número de pacientes e seguimento prolongado são necessários para confirmar sua eficácia e segurança.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright Statement - Policy Proposal for Open Access Journals
Authors who publish in the Brazilian Journal of Natural Sciences (BJNS) agree to the following terms: 1 - Authors retain the copyright and grant the journal the right to first publication, with the work simultaneously licensed under the Creative Commons Attribution License allowing sharing of the work with recognition of the authorship of the work and initial publication in this journal. 2 - Authors are authorized to assume additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (eg, publishing in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal. 3 - Authors are allowed and encouraged to publish and distribute their work online (eg in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes, as well as increase the impact and citation of published work. This is an open access article under the CC-BY license
(http://creativecommons.org/licenses/by/4.0)
References
KANSAL, R. et al. T-cell directed CAR therapy for autoimmune diseases: insights from a new therapeutic modality. Nature Reviews Rheumatology, v. 15, n. 4, p. 191-204, 2019. DOI: 10.1038/s41584-019-0178-0.
MAUDE, S. L. et al. Tisagenlecleucel in Children and Young Adults with BCell Lymphoblastic Leukemia. The New England Journal of Medicine, v. 378, n. 5, p. 439-448, 2018. DOI: 10.1056/NEJMoa1709866.
SCHUSTER, S. J. et al. Tisagenlecleucelin Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. The New England Journal of Medicine, v. 380, n. 1, p. 45-56, 2019. DOI: 10.1056/NEJMoa1804980.
GUFFROY, A. et al. CAR-T cells for treating systemic lupus erythematosus: a promising emerging therapy. Joint Bone Spine, v. 91, n. 5, p. 105702, 2024. DOI: 10.1016/j.jbspin.2024.105702.
MACKENSEN, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nature Medicine, v. 28, n. 10, p. 2124–2132, 2022. DOI: 10.1038/s41591-022-02017-5.
MALE, D. Imunologia. 8 ed. Rio de Janeiro: GEN Guanabara Koogan, 2014. E-book. ISBN 9788595151451.
SIEGEL, C. H.; SAMMARITANO, L. R. Systemic Lupus Erythematosus. JAMA, v. 331, n. 17, p. 1480-1491, 2024. DOI: 10.1001/jama.2024.2315.
TANAKA, Y. State‐of‐the‐art treatment of systemic lupus erythematosus. International Journal of Rheumatic Diseases, v. 23, n. 4, p. 465–471, 2020. DOI: 10.1111/1756-18X.13817.
KANSAL, R. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Science Translational Medicine, v. 11, n. 482, p.eaav1648, 2019. DOI: 10.1126/scitranslmed.aav1648.
MULLER, F. et al. CD19 CAR T-Cell Therapy in Autoimmune Disease – A Case Series with Follow-up. The New England Journal of Medicine, [S. l.], v. 390, n. 8, p. 687-700, 2024. DOI: 10.1056/NEJMoa2308917.
WANG, W. et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Annals of the Rheumatic Diseases, [S. l.], v. 83, n. 10, p. 1304-1314, 2024. DOI: 10.1136/ard-2024-225785.
BOULOUGOURA, A. et al. Journal Club: Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus. ACR Open Rheumatology, [S. l.], v. 5, n. 11, p. 624-628, 2023. DOI: 10.1002/acr2.11614.
HE, X. et al. Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells. Autoimmunity Reviews, [S. l.], v. 24, n. 1, p. 103692, 2025. DOI: 10.1016/j.autrev.2024.103692.
CHINA IMMUNOTECH (BEIJING) BIOTECHNOLOGY CO., LTD. An exploratory clinical study of YTS109 cell in subjects with relapsed/refractory autoimmune diseases. Bethesda: ClinicalTrials.gov, 2025. Identifier: NCT06978647.
CHINA IMMUNOTECH (BEIJING) BIOTECHNOLOGY CO., LTD. An exploratory clinical study of YTS109 cell in subjects with refractory disease systemic lupus erythematosus. Bethesda: ClinicalTrials.gov, 2025. Identifier: NCT06943937.
BRISTOL MYERS SQUIBB. A phase 1, multicenter, open-label study of BMS-986515, healthy donor allogeneic CD19-targeted chimeric antigen receptor (CAR) T cells, in participants with severe, refractory autoimmune diseases. Bethesda: ClinicalTrials.gov, 2025. Identifier: NCT07115745.
SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY CO., LTD. An exploratory clinical study on the safety and efficacy of CD19/BCMA chimeric antigen receptor NK cells in the treatment of B cell-related autoimmune diseases in children. Bethesda: ClinicalTrials.gov, 2025. Identifier: NCT06792799.
THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY. An open, single-arm, single-center clinical study assessing the safety and efficacy of BCMA-CD19 targeted chimeric antigen receptor T-cell therapy in multiple refractory autoimmune diseases. Bethesda: ClinicalTrials.gov, 2025. Identifier: NCT06794008.
SHENZHEN GENO-IMMUNE MEDICAL INSTITUTE. Management of autoimmune conditions with mesenchymal stem cells (MSCs) and CAR-T cells. Bethesda: ClinicalTrials.gov, 2024. Identifier: NCT06435897.
SHENZHEN GENO-IMMUNE MEDICAL INSTITUTE. CAR-T cells targeting B cell related autoimmune diseases. Bethesda: ClinicalTrials.gov, 2022. Identifier: NCT05459870.